<DOC>
	<DOCNO>NCT02201901</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy , safety , tolerability sofosbuvir ( SOF ) /velpatasvir ( VEL ) fix dose combination ( FDC ) without ribavirin ( RBV ) 12 week SOF/VEL FDC 24 week adults chronic hepatitis C virus ( HCV ) infection Child-Pugh-Turcotte ( CPT ) class B cirrhosis .</brief_summary>
	<brief_title>Sofosbuvir/Velpatasvir Fixed-Dose Combination Adults With Chronic HCV Infection Child-Pugh Class B Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing able provide write informed consent HCV RNA &gt; 10^4 IU/mL screen Chronic HCV infection ( â‰¥ 6 month ) Confirmed CPT class B ( 79 ) screening Current prior history solid organ transplantation , significant pulmonary disease , significant cardiac disease , porphyria Inability exclude hepatocellular carcinoma ( HCC ) image within 6 month baseline/Day 1 Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Screening ECG clinically significant abnormality Prior exposure SOF nucleotide analogue HCV nonstructural protein 5B ( NS5B ) inhibitor HCV NS5A inhibitor Laboratory result outside acceptable range screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Sofosbuvir</keyword>
	<keyword>Velpatasvir</keyword>
	<keyword>SOF/VEL</keyword>
	<keyword>GS-5816</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>CPT-B</keyword>
</DOC>